Is the generic drug of sotorasibu (AMG510) the same as the original drug?

Sotoracib (AMG510), as a new targeted drug targeting KRAS mutations, has shown the potential to combat a variety of malignant tumors, especially in non-small cell lung cancer with frequent KRAS gene mutations. Dysfunction of the KRAS protein is an important target for the growth and spread of these cancers, and sotoraxib can inhibit this target, thereby curbing tumor development. Compared with traditional chemotherapy drugs, the specificity of sotoraxib enables it to be more accurate during treatment and reduce damage to normal cells. Verified by a series of clinical trials, it has become an important part of the treatment for some patients.

Regarding the differences between the generic drug of Sotorasibu and the original drug, the original drug is an innovative drug developed and patented by Amgen Pharmaceuticals in the United States. Its research and development process has undergone rigorous testing and review. Generic drugs are similar drugs produced and sold by other pharmaceutical companies after the patent of the original drug expires. Although generic drugs are similar to original drugs in terms of active ingredients, there may be subtle differences in production methods, raw material selection, and quality control, which may affect the final efficacy and safety of the drug. There may also be subtle differences in packaging and storage conditions.

In summary, sotorasiib provides a new treatment strategy for KRAS mutated cancer patients. However, when choosing a drug source, you must weigh the pros and cons between generic drugs and original drugs, and make a choice based on the patient's specific situation and needs. This is the key to ensuring treatment effectiveness and safety. Currently on the market, there are original versions of Sotorasibu, Hong Kong original version and European original version, both priced at tens of thousands of RMB, while generic versions are more widely available, such as Laos Lucius, Daxiong Pharmaceutical, etc., priced at 1-2,000 RMB.